Recent Advances in the Oral Delivery of Biologics

1* Shruti S Zanjare 2* Sonali S Sonavane
1* Pratibhatai Pawar college of pharmacy shrirampur
2* Assistant professor of Pratibhatai Pawar college of pharmacy shrirampur

Abstract:

The majority of patients find that the oral route of drug administration is the most convenient, easy to follow, non- invasive, and physician-preferred method. However, oral biologic administration is not as beneficial as other routes because of mucosal permeability and various gastrointestinal barriers that limit the systemic absorption of complex macromolecules after ingestion. Because of their large molecular size, which results in extremely poor permeability across the intestinal mucosa, biologics are sensitive to the harsh environment of the gastrointestinal tract and thus play a significant role in the treatment of therapeutic interventions such as Chronic ailments, metabolic disease aging, and inflammatory disorders. Many drug delivery systems and pharmaceutical technologies, such as micelles, nano carriers, lipid-based carriers, and cyclodextrins, have been explored to enhance oral drug absorption. This article will first address the drug discovery, intensive research, and design that have enhanced the growth of biologics in recent decades and further accelerated the way we administer the medication in a clinical setting. physiological barriers to oral delivery of biologics and addresses various approaches to enhance the efficacy of oral delivery; furthermore, this conversation will encompass the diverse benefits and constraints of drug delivery systems as well as the general perception and promise of this emerging clinical area.

Keywords: Absorption enhancers; biologics; drug delivery; Gastrointestinal barriers; insulin; microneedle pill; oral delivery.

1.Introduction:

Biologics-a product that is produced from living organisms or contains components of living organisms. Have transformed the treatment of numerous ailments, including diabetes, cancer, and inflammatory diseases (such as rheumatoid arthritis and inflammatory bowel disease [ibd]). While they have been used clinically for a long time-nearly a century, in the case of insulin-their development and use have increased significantly over the past 20 years due to advancements in biotechnology and new knowledge of biology and disease processes. In 2018, eight out of ten top selling drugs (global sales in us dollars) were biologics. (1)

The production, administration, clinical efficacy, and cost of biologics are all affected by their differences from chemically derived "conventional" medicines. In comparison to small-molecule drugs like aspirin, biologics are typically larger in molecular weight and have a more diverse structure. Because they are large, complex molecules, biologics are highly susceptible to the physical and chemical conditions of the gastrointestinal (gi) environment; in

fact, with a few exceptions, biologics are currently administered by injection. With a few notable exceptions, biologics are currently administered by injection. Nevertheless, oral administration is the most practical and preferred mode of drug administration.(2-5) compared to injection, oral administration offers additional advantages. For instance, insulin administered orally more closely resembles the physiology of endogenous insulin secreted by the pancreas, resulting in lower levels of systemic insulin and a reduction in hypoglycemic episodes and weight gain issues.(6) additionally, insulin administered orally minimizes needle-related complications and costs.research on the oral delivery of biologics has been conducted for nearly a century, but the current state of clinical practice remains unchanged in abstract: patients generally prefer to take medications orally because it is more convenient. Despite nearly a century of research on oral biologic delivery, the state of clinical practice today is largely unchanged in nevertheless, the increasing number of biologics on the market has accelerated this research, and when combined with recent advancements in materials, research into oral delivery of biologics is yielding more clinically relevant drug- delivery technologies that have the potential to make oral administration of biologics a practical option in terms of administration options for these therapeutics.(7-9) The process of producing biologics is outside the purview of this article; instead, it will discuss the drug delivery of biologics and recent developments in this field.

2.Physiological barriers to oral delivery of biologics:

Overcoming the various physiological barriers in the gastrointestinal tract (git), which are intended to stop the absorption of foreign substances, such as dangerous pathogens or their products, from the external environment (i.e., the gut lumen)), is a significant obstacle to achieving clinically relevant oral delivery of biologics. Proteins can be broken down into constituent amino acids, dipeptides, and tripeptides by ph-induced proteolysis.(10) proteolytic enzymes in the gut lumen (e.g., pepsin, trypsin, chymotrypsin), proteolytic enzymes at the brush border membrane (e.g., endopeptidases), and the efflux pump p-glycoprotein are examples of biochemical barriers however, the intestinal epithelium is the largest and most significant barrier for the absorption of biologics; even though it is only one cell thick, the cells are arranged to form a nearly continuous cell membrane barrier facing the lumen; additionally, the mucus layer that sits above the epithelium and varies in thickness depending on the region of the gut may also act as a barrier, impeding the diffusion of biologics to the underlying epithelium. (10)

The thin and specialized sheets of extracellular matrix found in the epithelia and connective tissue can impede macromolecule penetration into the space beneath the epithelium, thereby restricting systemic absorption.(11,12)this is one of the main reasons why biopharmaceuticals have an oral bioavailability of less than 1%.(13)

3.Strategies for improving oral delivery of biologics-

3.1.Protect the biologic from acid and enzymatic degradation:

Reducing acid degradation is one way to increase the bioavailability of biologic medications. This can be done by delivering the medication in enteric-coated systems, which are well-established and won't be covered in this article.(14) biotherapeutics can be shielded from the proteolytic enzymes found in the intestinal environment by co- administration of protein and peptide drugs with protease inhibitors.(15) additionally, certain biologics, especially peptides, can have their chemical structures changed to increase their stability in gl fluids. One such method is the "cyclisation" approach (15).certain biologics, such as those derived from sharks and llamas, have higher intrinsic physicochemical stability against enzymatic degradation in the gastrointestinal tract (git) and may be suitable for oral delivery; the latter is being studied as an oral delivery anti-tumour necrosis factor-alpha biologic for the treatment of ibd. (16) it should be emphasized that safeguarding the biologic medication against acid and enzymatic breakdown is a crucial prerequisite. The strategies that follow, which aim to enhance oral delivery of biologics, must also make sure that this requirement is satisfied.

3.2.Increase the contact time of the biologic with the absorptive epithelium.

Preventing the luminal loss of the medication is the goal of this approach, which is crucial given the length of the intestines.and put it in close proximity to the absorbent epithelium at high concentrations.'mucoadhesive' materials are generally polymers that can interact with mucus in both ionic and non-ionic ways. This can help extend the duration of the medication's residence time at the absorption site, resulting in enhanced absorption. (17) among the natural mucoadhesive polymers are chitosan, pectin, gelatine, sodium alginate, guar gum, and xanthan gum.(18); among the synthetic mucoadhesive polymers are cellulose derivatives, poly(acrylic acid) polymers, poly(ethylene glycol), poly(ethylene oxide), poly(vinyl pyrrolidone), and poly(vinyl alcohol).(19) numerous materials have been tested for oral biologic delivery, with varying degrees of success.(20) salmon calcitonin (sct)is a therapeutic polypeptide that can be delivered orally through a mucoadhesive "transdermal patch-like" system that is encased in gastro-resistant hard gelatin capsules. (21) the system was based on mucoadhesive polymers, specifically carbopol 934, pectin, and sodium carboxymethylcellulose, and it significantly increased the amount of internal sct absorption in vivo. Gupta et al. Have looked into similar mucoadhesive patches for oral delivery of exenatide and insulin. (22) In the rat jejunum, surgical implantation of these systems led to a 42% reduction in blood glucose levels; in contrast, the group treated with insulin solution (control) did not exhibit any such effect. Relative bioavailability of exenatide and insulin increased significantly when compared to intestinal injections, increasing by 13 and 80 fold, respectively. (22) Even though mucoadhesive systems have shown promise for oral biologic delivery in vitro and in vivo, this strategy may face limited efficacy, particularly with larger biologics (such as monoclonal antibodies). It makes sense that merely extending the biotherapeutic's residence time at the absorbent surface might not be enough to achieve a clinically meaningful increase in bioavailability. Restricted capacity of hydrophilic medications with molecular weight orders of magnitude above 500da to pass through the intestinal epithelium. Moreover, it is not yet known how intestinal mucus turnover may impact these systems' functions.(20)

additionally, there might be problems if these systems are used in conditions like ibd that are linked to mucus abnormalities.

4.Make the mucosal barrier more permeable

The intestinal mucus barrier and the epithelial barrier can both be modified. The mucus barrier can be modified by using mucolytic (mucus-breaking) agents, like n- acetylcysteine, to improve the diffusion of large molecule biologics; however, since the epithelium is usually the rate- limiting barrier, not the mucus, it is usually more advantageous to manipulate this. The epithelial barrier can be modified by a number of chemical absorption enhancers, such as surfactants and other materials that open epithelial tight junctions. (23)

5.Surfactants

These materials have a hydrophilic and a hydrophobic component. They can adsorb onto system interfaces and change the free energy and tension between the two, which causes the intestinal epithelial plasma membrane to fluidize and temporarily open epithelial tight junctions, which allows macromolecules to pass through.(24) the main candidates currently being used in the development of oral peptide formulations are surfactants based on medium-chain fatty acids (e.g., sodium caprate, sodium caprylate, and n-[8-(2-hydroxybenzoyl) amino] caprylate [snac]), bile salts, and acyl carnitines.(25) technologies that use these materials and are undergoing clinical trials include the "eligen " technology (novo- nordisk) and the "gastro- intestinal permeating technology" (novo-nordisk). A snac formulation for the oral delivery of the long-acting glp-1 analogue, semaglutide (novo nordisk), for type 2 diabetes mellitus was recently reported to have successfully completed the first phase illa trial.large doses of snac are already available in vitamin b12 tablets, and the 703-person trial met its main goal of showing improvements in hba1c levels for three oral semaglutide doses (3 mg, 7 mg, and 14 mg) compared with placebo.(26)the biopharmaceutical company chiasma, based in israel, developed the "transient permeability enhancer" (tpe) technology currently used in mycapssa capsule formulations for the maintenance therapy of adult patients with acromegaly. Currently, three global phase iii studies are being conducted with promising potential regarding mycapssa (chiasma) capsules.(27).the active ingredient in this formulation is the peptide octreotide, an analogue of somatostatin. The combination of pharmaceutical excipients in this formulation results in an oily suspension of hydrophilic particles in a hydrophobic matrix, which can be enhanced by tpe technology for octreotide's oral bioavailability. (28) the hydrophilic constituent solubilizes octreotide and other excipients. The surfactants in this formulation cause tight junctions to expand momentarily, protecting the drug from the digestive enzymes so that it can pass through the intestinal epithelial membrane and enter the bloodstream. (28)

6.Tight junction-opening permeation enhancers

Decades of research in this field have identified a wide range of materials capable of opening epithelial tight junctions, including surfactants. Opening epithelial tight junctions is a potentially useful strategy to increase the permeability of the intestinal epithelium because the medication can avoid entering the epithelial cells and be

present in an environment rich in enzymes during its absorption process. Although many materials have demonstrated the ability to reversibly open epithelial tight junctions, chitosans are likely the most thoroughly studied compound. The process involves widening the paracellular space, which is normally too small to accommodate biologics. However, tight junction-opening must be reversible so that the physiological role of the epithe- lium is maintained as a tight barrier.(29) it should be noted that drug delivery approaches that use chemicals to modify the mucosal barrier-namely, absorption enhancers, such as surfactants and tight junction-opening agents-rely on concentration- dependent effects on barrier permeability. As a result, potential variability in absorption as a result of fasted and fed state, as well as the volume of water used for swallowing solid dosage forms, may be related to this method's clinical implications. Additionally, the long-term effects of repeatedly altering gut perme-ability remain unclear and require careful evaluation.

7.Make the biologic drug or drug delivery system more permeable

Chemical modification may be able to impart the biologic's epithelial-perme-ating properties, depending on the type of biologic.(15) the biotherapeutic's ability to cross the intestinal epithelium can also be increased by attaching it to another molecule that can also do so. Usually, this "transport-enabling" molecule passes through the intestinal epithelium via a particular receptor expressed in the intestinal epithelial cells. The two entities can be attached chemically (conjugation) or through fusion technologies mediated by biotechnology. Examples of transport-enabling molecules are other peptides or proteins that use biological transport processes to traffic across the epithelium.(30) researchers have integrated biotherapeutics into drug carrier systems that can pass through the intestinal barrier in addition to modifying the biologic to increase its propensity to do so. (31)Biodegradable polymeric nanoparticles, which are based on nanometer-scale biologic carriers, offer a number of benefits. For instance, some nanoparticles protect the therapeutic drug from the acid and enzymes found in the gastrointestinal tract. Additionally, selective drug delivery can be accomplished by targeting specific receptors on the surface of intestinal epithelial cells. On the other hand, nanoparticle carriers, like large molecule biologics, are generally poorly absorbed across the intestinal mucosa.(32)Because of this potential for poor diffusion in intestinal mucus and their inability to cross the intestinal epithelium, drug carriers based on nanoparticles have been developed with specific materials on their surface that function as ligands for biological transport receptors expressed in intestinal epithelial cells. Several research groups have investigated these delivery systems, which include nanoparticles that take advantage of the intestinal epithelial transport pathways of immunoglobulin g (igg) and vitamin b12 have been investigated by numerous research teams.(23) one biological transport pathway that has shown considerable Potential for intestinal nanoparticle transport is the neonatal fc Receptor (fcrn), which is present in the human intestinal epithe- Lium and participates in the intestinal transport of igg and serum Albumin.(33)when administered orally to mice, fcrn-targeted polymer nanoparticles demonstrated potential for oral insulin delivery.(31) these nanoparticles crossed the intestinal epithelium and entered the systemic circulation with a higher absorption efficiency than non- fcrn-targeted nanoparticles. In mice expressing the receptor, the insulin-containing nanoparticles caused a prolonged hypoglycaemic effect in comparison to the control group.

7.1 Therapeutic use concept of hollow and solid microneedle pills in the gastrointestinal tract

In hollow microneedles, the drug reservoir is compressed through peristalsis, releasing the drug through the needles. In solid microneedles, The drug is formulated into microneedles. These penetrate the tissue and break off from the pill, leaving the needle to release the drug in a controlled manner.



Fig.1: Therapeutic use concept of hollow and solid microneedle pills in the gastrointestinal tract

(Fcrn-knockout mice).(31) fcrn- targeted polymer nanoparticles were investigated for exenatide oral delivery34 in a different study.(34)these setups moved around delivery of exenatide by these nanoparticles led to an extended hypoglycaemia compared with subcutaneous exenatide injection; this was observed faster and to a greater extent than with unmodified nanoparticles across the intestinal epithelium.while preclinical research shows promising results and potential benefits, there are several obstacles to overcome in the development of strategies based on nanomedicines:

Low therapeutic loading capacity is a potential drawback for nanoparticle-based carriers, especially when dealing with larger biologics like monoclonal antibodies.(23) the biological pathways that these systems use often have a low trans-port capacity, so the delivery capacity could also be a problem. (35) the main problem is the attachment or adsorption of materials as normal constituents of intestinal biofluid, such as peptides and proteins, adsorbing on the surface of nanocarriers, which influences their ability to target biological receptors and use these systems for epithelial transport. Complex nanocarriers may undergo extensive degradation or alteration in the git in the presence of highly complex intestinal biofluid.(23)

8.Overcome the mucosal barrier using 'smart' ingestible devices

By using various techniques, such as ultrasound and microneedles, ingestible "smart" devices can improve the intestinal absorption of biologics while also shielding the therapeutic from the harsh environment of the gastrointestinal tract (25) rani therapeutics is developing the microneedle oral delivery technology in the us, and the company reports that preclinical research has produced positive outcomes thus far.(36) using a capsule that is meant to stay whole in the stomach, the medication is injected into the intestinal wall of the small intestine (see figure 2).due to the intestinal mucosa's lack of pain receptors, this procedure is painless and has demonstrated remarkable insulin bioavailability that is on par with or superior to subcutaneous injections. The benefit of this technology is that in addition to the delivery of low- to-medium larger biologics, like antibodies, it might also be able to deliver molecular weight biologics.(36) when the pill reaches the desired location in the git, the ph-responsive coating on the capsules, as depicted in figure 2, dissolves and releases the microneedles. For systems that have hollow microneedles, this process occurs when the coating dissolves.for systems with solid microneedles, the drug is formulated into the microneedles that penetrate the tissue and break off from the pill, leaving the needle to release the drug in a controlled manner based on the needle formulation. The drug reservoir is compressed through peristalsis, releasing the drug through the needles.(37) known as the "self-orienting millimeter-scale applicator" (soma), this novel system for the oral delivery of biologics uses this same shape and low center of gravity to mimic the behavior of the leopard tortoise (stigmochelys pardalis), a tortoise with a steeply domed shell that it uses to self-orient itself should it roll onto its back. This research was published in a recent landmark study.to physically insert a biodegradable microneedle through the stomach mucosa for systemic administration of biotherapeutics (refer to figure 3). The device's ability to successfully deliver drugs through the mucosal layer was demonstrated when it was loaded with human insulin and given to swine.(38)

9.Potential for clinical translation of oral biologics

9.1.Delivery strategies

While many of the drug delivery strategies discussed above have demonstrated positive results and potential in vivo and in vitro, they have not yet been used in patients. Unfortunately, safety and efficacy are often mutually exclusive with many of the delivery approaches discussed above, so such strategies are unlikely to progress to the clinic. Furthermore, it is well known that many of the permeation enhancers in current oral peptide clinical trials cause small intestinal epithe- lial damage(17). Despite tissue damage being a concern, oral delivery devices for biologics are showing significant potential it is unknown whether repeated, chronic dosing of these absorption enhancers could override the body's repair mechanisms, even though they are frequently transient and reparable.

Figure 2

8.1 Mechanical active pharmaceutical ingredient localisation and injection for oral gastric delivery

(a) The self-orienting millimeter-scale applicator (soma) localizes to the stomach lining, orients its injection mechanism toward the tissue Wall and injects a drug payload through the mucosa. The drug dissolves and the rest of the device passes out of the body.

(b) A comparison between the shape of the leopard tortoise (stigmochelys pardalis) and that of the soma. The soma quickly orients and remains stable in the Stomach environment after reaching its preferred orientation.



Fig.2: An ingestible self-orienting system for oral delivery macromolecules.

A safer alternative could be one that relies on improving the Intestinal absorption of biologics by exploiting biological trans- Port processes to achieve delivery without damaging the tissue;However, these are likely to be faced by limited capacity and may Be best suited for more potent biologics. Such devices need to Clearly demonstrate safety on repeated administration in humans; It seems that efficiency is not an issue. Furthermore, the costs of These technologies are currently unclear, but are likely to be high In the short-to-medium term in which case, it will be critical to Give careful consideration to the selection of the biologic, disease Area and patient population for use of these drug delivery systems.

10.Advantages of oral delivery systems:

- Patients who receive formulations orally typically comply with oral delivery more than those who receive parenteral routes like subcutaneous, intravenous, and intramuscular injections, as well as inhalation for asthma medication.

- Oral drug administration involves placing pills, tablets, syrups, emulsions, powders, suspensions, and other forms of medication in the mouth and swallowing it. This allows for targeted treatment of pathological conditions, such as infections, inflammations, and stomach and colorectal cancers, within specific gl tract regions. Because of its many advantages, including cost-effectiveness, ease of

administration, and patient compliance, oral drug administration is an effective option for treating a variety of fatal diseases.

- Oral pharmaceutical formulations intended for human consumption account for about 90% of the global market share, according to current estimates. Of these, 84% are the best-selling oral pharmaceutical products, with a current market value of $35 billion. Oral drug administration is the most convenient mode of administration for patients, as it allows them to self-administer treatments in non-sterile conditions, which can also help with patient compliance.

11.Future trends oral drug delivery:

Oral delivery is the most common mode of administration for both adult and pediatric patients. However, advances in formulation strategies have raised issues with conventional oral formulations. One such advancement is the establishment of reliable in vitro- in vivo correlation models, which deserve consideration in the future because they predict better in vivo performance and can produce data that offers a cost-benefit analysis compared to existing formulations. Another development is the acceleration of the transition from laboratory to commercial production scale formulations. A target patient population must be considered when designing new formulations. Adult drug formulation uses nanoparticle technologies to create better pediatric formulations. The time it takes to bring a lead compound from drug discovery to clinical trials is anticipated to be shorter than it is now, and pharmaceutical researchers will face many challenges in their quest for better therapy in oral formulations

12.Conclusion:

There is no significant impact in the clinic studies up to date although the research in the oral delivery of biologics has significant progress towards medical advancement. It is yet to be proven significant for the patients with the drug delivery strategies in possible pharmacokinetic scenarios. Although there is a lack of clinical translation success safety And efficacy that are mutually exclusive which reflects the high effectiveness in the physiological barriers in the git to make oral delivery of biologics a clinical reality. There should be an increased knowledge of physiological barriers with unmatched recent developments in materials which are propelling in this area.

13.Reference:

1. Urquhart l. Top drugs and companies by sales in 2018. Nat rev Drug discov 2019. Doi: 10.1038/d41573-019-00049-0. page no.18(245).

2. Eek d, krohe m, mazar i et al. Patient-reported preferences for oral Versus intravenous administration for the treatment of cancer: a review Of literature. Patients prefer adherence 2016. Doi: 10.2147/ppas106629. Page no.1609-1621.

3. Pridgen em, alexis f & farokhzad oc. Polymeric nanoparticle drug Delivery technologies for oral delivery applications. Expert opin Drug deliv 2015;vol.12(9). Doi: 10.1517/17425247.2015.1018175.page no.1459-1473.

4. Sosnik & Augustine r. Challenges in oral drug delivery of antiretrovirals And the innovative strategies to overcome them. Adv drug deliv rev 2016. Doi:10.1016/jaddr.2015.12.022.page no.103:105-120.

5. García-pérez le, alvarez m, dilla t et al. Adherence to therapies In patients with type 2 diabetes. Diabetes ther 2013;4(2). Doi: 10.1007/s13300-013-0034-y.page no.175-194.

6. Gedawy a, martinez j, al-salami h & dass cr. Oral insulin delivery: Existing barriers and current counter-strategies. J pharm pharmacol 2018;70(2):. Doi: 10.1111/jphp.12852. page no .197-213.

7. Harrison ga. Insulin in alcoholic solution by the mouth. Bmj 1923;2(3286). Doi: 10.1136/bmj.2.3286.1204.page no.1204-1205.

8. Murlin jr, sutter cc, allen rs & piper ha. Some favorable effects from The alimentary administration of insulin. Endocrinology 1924;8(3). Doi: 10.1210/endo-8-3-331.page no.331-339.

9. Salen e. Einige Versuche mit peroraler Darreichung von Insulin [attempts with oral insulin administration]. Acta medica scandinavica 1924;60(1). Doi: 10.1111/j.0954-6820.1924.tb15268.x.page no74-87.

10. Khanvilkar k, donovan md & flanagan dr. Drug transfer through mucus. Adv drug deliv rev 2001;48(2–3). Doi: 10.1016/s0169-409x(01)00115-6
Page no 173-193.

11. Mantaj j, abu-shams t, enlo-scott z et al. Role of the basement membrane As an intestinal barrier to absorption of macromolecules and nanoparticles.Mol pharm 2018;15(12). Doi: 10.1021/acs.molpharmaceut.8b01053.page no.5802-5808

12. Vllasaliu d, falcone fh, stolnik s & garnett m. Basement membrane Influences intestinal epithelial cell growth and presents a barrier to the Movement of macromolecules. Exp cell res 2014;323(1). Doi: 10.1016/jyexcr.2014.02.022. page no.218-231

13. Mahato ri, narang as, thoma l & miller dd. Emerging trends in oral delivery Of peptide and protein drugs. Crit rev ther drug carrier syst 2003;20 (2–3). Doi: 10.1615/critrevtherdrugcarriersyst.v20.i23.30.page no.153-214

14. Maher s, ryan b, duffy a & brayden dj. Formulation strategies to improve oral Peptide delivery. Pharm pat anal 2014;3(3). Doi: 10.4155/ppa.14.15.page no.313-336.

15. Bruno bj, miller gd & lim cs. Basics and recent advances in peptide and Protein drug delivery. Ther deliv 2013;4(11). Doi: 10.4155/tde.13.104 .page no.1443-1467.

16. Crowe js, roberts kj, carlton tm et al. Preclinical development of a novel, Orally-administered anti-tumour necrosis factor domain antibody for The treatment of inflammatory bowel disease. Sci rep 2018;8(1). Doi: 10.1038/s41598-018-23277-7. Page no.4941.

17. Bernkop-schnürch a. Mucoadhesive systems in oral drug delivery. Drug discov today technol 2005;2(1). Doi: 10.1016/j.ddtec.2005.05.001.page no.83-87.

18. Cook sl, bull sp, methven l et al. Mucoadhesion: a food perspective. Food hydrocolloids 2017;72 Doi: 10.1016/j.foodhyd.2017.05.043.page no 281-296.

19. Rossi s, vigani b, sandri g et al. Recent advances in the mucus-interacting Approach for vaginal drug delivery: from mucoadhesive to Mucus-penetrating nanoparticles. Expert opin drug deliv 2019;16(8). Doi: 10.1080/17425247.2019.1645117.page no.777-781.

20. Homayun b, lin x & choi hj. Challenges and recent progress in oral drug Delivery systems for biopharmaceuticals. Pharmaceutics 2019;11(3). Doi: 10.3390/pharmaceutics11030129. Page no :129.

21. Gupta v, hwang bh, lee j et al. Mucoadhesive intestinal devices for oral Delivery of salmon calcitonin. J control release 2013;363(6427) Doi: 10.1016/j.jconrel.2013.09.004. page no 172-762 .

22. Gupta v, hwang bh, doshi n et al. Delivery of exenatide and insulin using Mucoadhesive intestinal devices. Ann biomed eng 2016;44(6). Doi: 10.1007/s10439-016-1558-x. Page no :1993-2007.

23. Vllasaliu d, thanou m, stolnik s & fowler r. Recent advances in oral delivery Of biologics: nanomedicine and physical modes of delivery. Expert opin drug Deliv 2018;15(8). Doi: 10.1080/17425247.2018.1504017. page no 759-770

24. Anderberg ek, nystrom c & artursson p. Epithelial transport of drugs in cell Culture. Vii: effects of pharmaceutical surfactant excipients and bile acids On transepithelial permeability in monolayers of human intestinal epithelial (caco-2) cells. J pharm sci 1992;81(9). Doi: 10.1002/jps.2600810908.page no 879-887.

25. Mccartney f, gleeson jp & brayden dj. Safety concerns over the use Of intestinal permeation enhancers: a mini-review. Tissue barriers 2016;4(2). Doi: 10.1080/21688370.2016.1176822.page no e1176822.

26. Castelli mc, wong df, friedman k & riley mg. Pharmacokinetics of oral Cyanocobalamin formulated with sodium n-[8-(2-hydroxybenzoyl)amino caprylate (snac): an open-label, randomized, single-dose, parallel-group Study in healthy male subjects. Clin ther 2011;33(7). Doi: 10.1016/j.clinthera.2011.05.088.page no 934-945.

27. Melmed s, popovic v, bidlingmaier m et al. Safety and efficacy of oral Octreotide in acromegaly: results of a multicenter phase iii trial. J clin Endocrinol metab 2015;100(4). Doi: 10.1210/jc.2014-4113.page no 1698-1708.

28. Tuvia s, pelled d, marom k et al. A novel suspension formulation enhances Intestinal absorption of macromolecules via transient and reversible transport Mechanisms. Pharm res 2014;31(8). Doi: 10.1007/s11095-014-1303-9.page no 2010-2021.

29. Thanou m, verhoef jc & junginger he. Oral drug absorption enhancement By chitosan and its derivatives. Adv drug deliv rev 2001;52(2). Doi: 10.1016/s0169-409x(01)00231-9.page no 117-126.

30. Amet n, wang w & shen wc. Human growth hormone-transferrin fusion Protein for oral delivery in hypophysectomized rats. J control release 2010;141(2). Doi: 10.1016/j.jconrel.2009.09.007.page no 177-182.

31. Pridgen em, alexis f, kuo tt et al. Transepithelial transport of fc-targeted Nanoparticles by the neonatal fc receptor for oral delivery. Sci transl med 2013;5(213). Doi: 10.1126/scitranslmed.3007049 .page no 213ra-167

32. Cao sj, xu s, wang hm et al. Nanoparticles: oral delivery for Protein and peptide drugs. Aaps pharmscitech 2019;20(5). Doi: 10.1208/s12249-019-1325-z .page no 190.

33. Kuo tt, baker k, yoshida m et al. Neonatal fc receptor: from Immunity to therapeutics. J clin immunol 2010;30(6). Doi: 10.1007/s10875-010-9468-4. Page no 777-789.

34. Shi y, sun x, zhang l et al. Fc-modified exenatide-loaded nanoparticles for Oral delivery to improve hypoglycemic effects in mice. Sci rep 2018;8(1) Doi: 10.1038/s41598-018-19170-y.page no 726.

35. Shen s, wu y, liu y & wu d. High drug-loading nanomedicines: progress, Current status, and prospects. Int j nanomedicine 2017;12 Doi: 10.2147/ijn.s132780.page no 4085-4109.

36. Biospace. First human study of "robotic" ranipill capsule to replace injections Announced by rani therapeutics. 2019. Available at: https://www.biospace.com/article/releases/first-human-study-of-and-quot-robotic-and-quot-ranipill-capsule-to-replace-injections-announced-by-rani-therapeutics/ (accessed january 2020)

37. Traverso g, schoellhammer cm, schroeder a et al. Microneedles for drug Delivery via the gastrointestinal tract. J pharm sci 2015;104(2). Doi: 10.1002/jps.24182. page no 362–367.

38. Abramson a, caffarel-salvador e, khang m et al. An ingestible self-orienting System for oral delivery of macromolecules. Science.2019;363(6427). Doi: 10.1126/science.aau2277.page no 611-615.